Function and genetics of dystrophin and dystrophin-related proteins in muscle

DOI: 10.1152/physrev.00028.2001
Physiological Reviews, 2002, 82, 291-329.

#	Paper	IF	Citations
962	Gene therapy of muscular dystrophy. **2002**, 11, 2355-62		93
961	A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. **2002**, 277, 45285-90		96
960	Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. **2002**, 11, 3333-44		122
959	Identification of Dp71 isoforms in the platelet membrane cytoskeleton. Potential role in thrombin-mediated platelet adhesion. **2002**, 277, 47106-13		22
958	Functional requirements for fukutin-related protein in the Golgi apparatus. **2002**, 11, 3319-31		101
957	Striated muscle cytoarchitecture: an intricate web of form and function. **2002**, 18, 637-706		479
956	Dystrobrevin dynamics in muscle-cell signalling: a possible target for therapeutic intervention in Duchenne muscular dystrophy?. *Neuromuscular Disorders*, **2002**, 12 Suppl 1, S110-7	2.9	23
955	Intermediate filaments and the function of the dystrophin-protein complex. **2002**, 12, 224-8		35
954	New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. **2002**, 1600, 38-44		106
953	Initial sequencing and comparative analysis of the mouse genome. **2002**, 420, 520-62		5376
952	Glycobiology of the neuromuscular junction. **2003**, 32, 915-29		59
951	U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. **2003**, 60, 557-66		55
950	Sarcoglycans in vascular smooth and striated muscle. **2003**, 13, 238-43		30
949	Muscle regeneration in amphibians and mammals: passing the torch. **2003**, 226, 167-81		58
948	Localizing synaptic mRNAs at the neuromuscular junction: it takes more than transcription. **2003**, 25, 25-31		23
947	Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). **2003**, 35, 84-9		361
946	Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. **2003**, 35, 367-71		396

945	Pharmacological strategies for muscular dystrophy. **2003**, 2, 379-90	167
944	An atomic model for actin binding by the CH domains and spectrin-repeat modules of utrophin and dystrophin. **2003**, 329, 15-33	66
943	Protein glycosylation in disease: new insights into the congenital muscular dystrophies. **2003**, 24, 178-83	72
942	Role of transcription factors in skeletal muscle and the potential for pharmacological manipulation. **2003**, 3, 300-8	9
941	Skeletal muscle basement membrane-sarcolemma-cytoskeleton interaction minireview series. **2003** , 278, 12599-600	52
940	Compensation for dystrophin-deficiency: ADAM12 overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins. **2003**, 12, 2467-79	57
939	The zebrafish as a model for muscular dystrophy and congenital myopathy. **2003**, 12 Spec No 2, R265-70	97
938	Archvillin, a muscle-specific isoform of supervillin, is an early expressed component of the costameric membrane skeleton. **2003**, 116, 2261-75	45
937	The basement membrane/basal lamina of skeletal muscle. **2003**, 278, 12601-4	280
936	Syntrophin gamma 2 regulates SCN5A gating by a PDZ domain-mediated interaction. **2003**, 278, 1915-23	88
935	Core 1 glycans on alpha-dystroglycan mediate laminin-induced acetylcholine receptor clustering but not laminin binding. **2003**, 278, 44868-73	28
934	Costameres: the AchillesNheel of Herculean muscle. **2003**, 278, 13591-4	324
933	Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. **2003**, 12, 1287-99	58
932	Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. **2003**, 130, 5851-60	187
931	Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. **2003**, 12, 1813-21	101
930	Binding of an ankyrin-1 isoform to obscurin suggests a molecular link between the sarcoplasmic reticulum and myofibrils in striated muscles. **2003**, 160, 245-53	154
929	Defective integrin switch and matrix composition at alpha 7-deficient myotendinous junctions precede the onset of muscular dystrophy in mice. **2003**, 12, 483-95	40
928	Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy. **2003**, 8, 274-83	7

927	Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. **2003**, 100, 7791-6	109
926	Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. **2003**, 17, 893-5	57
925	Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. **2004**, 13, 379-88	101
924	Tyrosine-phosphorylated and nonphosphorylated isoforms of alpha-dystrobrevin: roles in skeletal muscle and its neuromuscular and myotendinous junctions. **2003**, 160, 741-52	76
923	Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. **2003**, 108, 1626-32	130
922	Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. **2003**, 304, 453-63	161
921	Glycosylation defects: a new mechanism for muscular dystrophy?. **2003**, 12 Spec No 2, R259-64	76
920	Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. **2003**, 13, 55R-66R	70
919	Genomics as a probe for disease biology. **2003**, 349, 969-74	66
918	Severe muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. **2003**, 94, 1744-50	28
917	Chapter 5 Pathology and pathogenesis of muscle diseases. **2003**, 67-98	
916	A role for the juxtamembrane domain of beta-dystroglycan in agrin-induced acetylcholine receptor clustering. **2003**, 23, 392-402	21
915	Abnormal dysbindin expression in cerebellar mossy fiber synapses in the mdx mouse model of Duchenne muscular dystrophy. **2003**, 23, 6576-85	68
914	Molecular organization of the extraocular muscle neuromuscular junction: partial conservation of and divergence from the skeletal muscle prototype. **2003**, 44, 1918-26	36
913	[Current aspects of myopathology]. **2003**, 60, 413-7	
912	Depolarization-induced contraction and SR function in mechanically skinned muscle fibers from dystrophic mdx mice. **2003**, 285, C522-8	22
911	Cross bridging proteins in nature and their utilization in bio- and nanotechnology. **2004**, 5, 33-49	12
910	[Utrophin, a way to cure Duchenne muscle dystrophy]. **2004**, 20, 442-7	6

909	C-terminal truncated dystrophin identified in skeletal muscle of an asymptomatic boy with a novel nonsense mutation of the dystrophin gene. **2004**, 56, 739-43	10
908	Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. **2004**, 15, 145-56	59
907	Antisense derivatives of U7 and other small nuclear RNAs as tools to modify pre-mRNA splicing patterns. **2004**, 2, 321-349	10
906	Schizophrenia genetics and dysbindin: a corner turned?. **2004**, 161, 1533-6	40
905	The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. **2004**, 279, 28387-92	148
904	Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. **2004**, 10, 829-43	93
903	The congenital and limb-girdle muscular dystrophies: sharpening the focus, blurring the boundaries. **2004**, 61, 189-99	52
902	Therapeutic strategies for Duchenne and Becker dystrophies. **2004**, 240, 1-30	24
901	Myospryn is a novel binding partner for dysbindin in muscle. **2004**, 279, 10450-8	53
900	Identification of a zebrafish model of muscular dystrophy. **2004**, 31, 537-40	62
899	Skeletal muscle function: role of ionic changes in fatigue, damage and disease. **2004**, 31, 485-93	95
898	Membrane traffic in skeletal muscle. **2004**, 5, 129-39	39
897	Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. **2004**, 5, 872-6	226
896	The building BLOC(k)s of lysosomes and related organelles. **2004**, 16, 458-64	138
895	Calcium signaling in isolated skeletal muscle fibers investigated under "Silicone Voltage-Clamp" conditions. **2004**, 40, 225-36	20
894	Muscular dystrophies. **2004**, 71, 161-8	6
893	Murine Hermansky-Pudlak syndrome genes: regulators of lysosome-related organelles. **2004**, 26, 616-28	166
892	The sarcolemma in the Large(myd) mouse. **2004**, 30, 585-95	15

891	Differential Diagnosis of Serum Creatine Kinase Elevation. **2004**, 79-86		
890	Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. **2004**, 15, 1065-76		118
889	Schizophrenia genetics: dysbindin under the microscope. **2004**, 27, 516-9		59
888	A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. *Neuromuscular Disorders*, **2004**, 14, 19-23	2.9	40
887	Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice. **2004**, 164, 711-8		23
886	Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. **2004**, 164, 727-37		138
885	New therapies for muscular dystrophy: cautious optimism. **2004**, 10, 516-20		55
884	Enhanced expression of the P2X4 receptor in Duchenne muscular dystrophy correlates with macrophage invasion. *Neurobiology of Disease*, **2004**, 15, 212-20	7.5	17
883	ZZ domain of CBP: an unusual zinc finger fold in a protein interaction module. **2004**, 343, 1081-93		72
882	Cellular and molecular regulation of muscle regeneration. *Physiological Reviews*, **2004**, 84, 209-38	47.9	1879
881	Patterning, prestress, and peeling dynamics of myocytes. **2004**, 86, 1209-22		45
880	Changes of phospholipid composition within the dystrophic muscle by matrix-assisted laser desorption/ionization mass spectrometry and mass spectrometry imaging. **2004**, 10, 657-64		100
879	Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. **2004**, 379, 479-88		61
878	Immunopathology and molecular genetics of dystrophinopathies. **2004**, 57, 313-21		3
877	Duchenne Muscular Dystrophy (DMD) Gene. **2005**,		
876	Muscular Dystrophies. **2005**, 274-275		
875	Enhanced laminin binding by alpha-dystroglycan after enzymatic deglycosylation. **2005**, 390, 303-9		65
874	A novel scheme of dystrophin disruption for the progression of advanced heart failure. **2005**, 1751, 73-81		27

873	Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse. **2005**, 562, 367-80	217
872	Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. **2005**, 8, 421-32	229
871	The dystroglycanopathies: the new disorders of O-linked glycosylation. **2005**, 12, 152-8	55
870	A novel paradigm for therapeutic basis of advanced heart failure--assessment by gene therapy. **2005**, 107, 31-43	8
869	Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice. **2005**, 286, 814-22	40
868	Association of alpha-dystrobrevin with reorganizing tight junctions. **2005**, 203, 21-30	12
867	Molecular heterogeneity of the dystrophin-associated protein complex in the mouse kidney nephron: differential alterations in the absence of utrophin and dystrophin. **2005**, 319, 299-313	28
866	Molecular Genetics of Muscle Disorders. **2005**, 369-392	0
865	Muscles of mice deficient in alpha-sarcoglycan maintain large masses and near control force values throughout the life span. **2005**, 22, 244-56	14
864	Problems and Hopes with Cell Therapy: The Case of Muscular Dystrophy. **2005**, 1-20	
863	Deficiency of alpha-sarcoglycan differently affects fast- and slow-twitch skeletal muscles. **2005**, 289, R1328-37	33
862	Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. **2005**, 289, C908-17	65
861	Satellite cells and utrophin are not directly correlated with the degree of skeletal muscle damage in mdx mice. **2005**, 289, C42-8	8
860	Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. **2005**, 79, 3146-62	40
859	Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. **2005**, 19, 750-60	121
858	Lipid imaging by gold cluster time-of-flight secondary ion mass spectrometry: application to Duchenne muscular dystrophy. **2005**, 46, 1388-95	110
857	Absence of Dp71 in mdx3cv mouse spermatozoa alters flagellar morphology and the distribution of ion channels and nNOS. **2005**, 118, 137-45	22
856	Neuroacanthocytosis Syndromes. **2005**,	4

855	Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. **2005**, 19, 79-81		45
854	Differentiation of Human Embryonic Stem Cells to Cardiomyocytes. **2005**, 301-324		1
853	Muscle costameric protein, Chisel/Smpx, associates with focal adhesion complexes and modulates cell spreading in vitro via a Rac1/p38 pathway. *Experimental Cell Research*, **2005**, 307, 367-80	4.2	20
852	Molecular basis of dystrobrevin interaction with kinesin heavy chain: structural determinants of their binding. **2005**, 354, 872-82		13
851	Identification of a functional CRE in the promoter of Fukuyama congenital muscular dystrophy gene fukutin. **2005**, 136, 1-11		5
850	Chronic treatment with agents that stabilize cytosolic IkappaB-alpha enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. *Neurobiology of Disease*, **2005**, 20, 719-30	7.5	38
849	Lack of dystrophin leads to the selective loss of superior cervical ganglion neurons projecting to muscular targets in genetically dystrophic mdx mice. *Neurobiology of Disease*, **2005**, 20, 929-42	7.5	14
848	The sarcoglycan-sarcospan complex localization in mouse retina is independent from dystrophins. **2005**, 53, 25-33		15
847	A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system. **2005**, 328, 507-16		45
846	Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. **2005**, 166, 1131-41		49
845	Mild dystrophic damage in the androgen-sensitive levator ani muscle of the mdx mouse. *Neuromuscular Disorders*, **2005**, 15, 48-56	2.9	9
844	Localized expression of specific P2X receptors in dystrophin-deficient DMD and mdx muscle. *Neuromuscular Disorders*, **2005**, 15, 225-36	2.9	15
843	The effect of respiratory muscle training with CO2 breathing on cellular adaptation of mdx mouse diaphragm. *Neuromuscular Disorders*, **2005**, 15, 427-36	2.9	9
842	A 1.3 kb promoter fragment confers spatial and temporal expression of utrophin A mRNA in mouse skeletal muscle fibers. *Neuromuscular Disorders*, **2005**, 15, 437-49	2.9	14
841	Understanding muscle architectural adaptation: macro- and micro-level research. **2005**, 181, 1-10		51
840	Spectrin, alpha-actinin, and dystrophin. **2005**, 70, 203-46		94
839	Stem Cells. **2006**,		
838	Scaffolding proteins at the Drosophila neuromuscular junction. **2006**, 75, 181-216		18

837	Cytoskeletal basis of ion channel function in cardiac muscle. **2006**, 2, 467-76		11
836	Retrograde signaling that regulates synaptic development and function at the Drosophila neuromuscular junction. **2006**, 75, 267-85		41
835	Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. *Experimental Cell Research*, **2006**, 312, 3872-9	4.2	28
834	Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers. **2006**, 119, 3733-42		99
833	Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. **2006**, 290, C616-25		99
832	Brain alpha-dystroglycan displays unique glycoepitopes and preferential binding to laminin-10/11. **2006**, 580, 3381-5		17
831	Pathological pattern of Mdx mice diaphragm correlates with gradual expression of the short utrophin isoform Up71. **2006**, 1762, 362-72		6
830	Interactions of intermediate filament protein synemin with dystrophin and utrophin. **2006**, 346, 768-77		70
829	S-myotrophin promotes the hypertrophy of skeletal muscle of mice in vivo. **2006**, 38, 1114-22		4
828	Cytoplasmic gamma-actin is not required for skeletal muscle development but its absence leads to a progressive myopathy. **2006**, 11, 387-97		91
827	Dystrophin Dp71f associates with the beta1-integrin adhesion complex to modulate PC12 cell adhesion. **2006**, 362, 954-65		26
826	Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. **2006**, 12, 122-9		90
825	Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. **2006**, 119, 1381-1391		6
824	Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein. **2006**, 395, 587-98		63
823	Proteomics success story. Towards early detection of breast and ovarian cancer: plasma proteomics as a tool to find novel markers. **2006**, 6 Suppl 2, 65-8		8
822	Age-related dystrophin-glycoprotein complex structure and function in the rat extensor digitorum longus and soleus muscle. **2006**, 61, 1119-29		21
821	Susceptibility genes for schizophrenia. **2006**, 60, S4-S10		8
820	Phosphorylation of dystrophin Dp71d by Ca2+/calmodulin-dependent protein kinase II modulates the Dp71d nuclear localization in PC12 cells. **2006**, 98, 713-22		15

819	Radiographic features of Golden Retriever muscular dystrophy. **2006**, 47, 574-80	15
818	Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. **2006**, 19, 19-42	283
817	Evidence for a role of inducible nitric oxide synthase in gastric relaxation of mdx mice. **2006**, 18, 446-54	5
816	Altered tachykinergic influence on gastric mechanical activity in mdx mice. **2006**, 18, 844-52	6
815	Blocking of striated muscle degeneration by serotonin in C. elegans. **2006**, 27, 253-8	26
814	Sarcolemmal ion channels in dystrophin-deficient skeletal muscle fibres. **2006**, 27, 367-73	22
813	New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. **2006**, 27, 375-86	46
812	Treatment of human disease by adeno-associated viral gene transfer. **2006**, 119, 571-603	116
811	Expression of alpha-dystrobrevin in blood-tissue barriers: sub-cellular localisation and molecular characterisation in normal and dystrophic mice. **2007**, 327, 67-82	9
810	Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. **2006**, 63, 1614-31	130
809	Beta-naphthoflavone represses dystrophin Dp71 expression in hepatic cells. **2006**, 1759, 152-8	6
808	Synaptic remodeling induced by axotomy of superior cervical ganglion neurons: Involvement of metalloproteinase-2. **2006**, 99, 119-24	7
807	Gene expression in male tick salivary glands is affected by feeding in the presence of females. **2006** , 63, 159-68	4
806	Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. **2006**, 209, 439-47	50
805	Assembly of a perivascular astrocyte protein scaffold at the mammalian blood-brain barrier is dependent on alpha-syntrophin. **2006**, 53, 879-90	61
804	Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. **2006**, 118, 412-21	58
803	Utrophin is a calpain substrate in muscle cells. **2006**, 33, 753-9	16
802	Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage. **2006**, 2, 222-30	40

801	Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. **2006**, 15, 2266-75	51
800	Ex vivo modification of cells to induce a muscle-based expression. **2006**, 6, 625-32	13
799	Duchenne Muscular Dystrophy. **2006**,	14
798	Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion. **2006**, 15, 213-21	68
797	Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle. **2006**, 15, 1423-35	51
796	Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. **2006**, 99, 407-14	176
795	Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle. **2006**, 103, 5385-90	61
794	Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH. **2006**, 387, 223-34	31
793	Skeletal Muscle Plasticity in Health and Disease. **2006**,	2
792	Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. **2006**, 119, 1537-46	91
791	Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. **2006**, 15, 3041-54	134
790	Cerebellar synaptic defects and abnormal motor behavior in mice lacking alpha- and beta-dystrobrevin. **2006**, 26, 2841-51	77
789	Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. **2006**, 20, 610-20	47
788	Dystrophin is required for appropriate retrograde control of neurotransmitter release at the Drosophila neuromuscular junction. **2006**, 26, 333-44	62
787	C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. **2006**, 14, 79-87	64
786	Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. **2006**, 13, 976-86	30
785	Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. **2006**, 20, 1724-6	51
784	Protein Misfolding, Aggregation, and Conformational Diseases. **2007**,	13

783	Congenital muscular dystrophies involving the O-mannose pathway. **2007**, 7, 417-25		56
782	MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. **2007**, 293, C451-7		104
781	SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. **2007**, 16, 327-42		111
780	Store-Operated Ca2+ Entry in Muscle Physiology. **2007**, 1, 87-95		
779	Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. **2007**, 32, 921-9		44
778	Functional roles for beta1,4-N-acetylgalactosaminyltransferase-A in Drosophila larval neurons and muscles. **2007**, 175, 671-9		25
777	Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. *Nucleic Acids Research*, **2008**, 36, 826-38	20.1	42
776	Sarcoglycan subcomplex expression in normal human smooth muscle. **2007**, 55, 831-43		18
775	Dystroglycan and protein O-mannosyltransferases 1 and 2 are required to maintain integrity of Drosophila larval muscles. **2007**, 18, 4721-30		54
774	Complete deletion of all alpha-dystrobrevin isoforms does not reveal new neuromuscular junction phenotype. **2007**, 14, 47-57		2
773	Dystrophin-dependent muscle degeneration requires a fully functional contractile machinery to occur in C. elegans. *Neuromuscular Disorders*, **2007**, 17, 56-60	2.9	12
772	Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. *Neuromuscular Disorders*, **2007**, 17, 209-20	2.9	40
771	Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy. *Neuromuscular Disorders*, **2007**, 17, 569-74	2.9	10
770	Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice. *Neuromuscular Disorders*, **2007**, 17, 639-50	2.9	21
769	Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. **2007**, 1772, 108-17		210
768	Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. **2007**, 1772, 243-62		79
767	Bex1 knock out mice show altered skeletal muscle regeneration. **2007**, 363, 405-10		29
766	Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. **2007**, 392, 142-50		27

765 Muscular dystrophy-related quantitative and chemical changes in adenohypophysis GH-cells in golden retrievers. **2007**, 17, 480-91 18

764 Ins and outs of therapy in limb girdle muscular dystrophies. **2007**, 39, 1608-24 38

763 Association of dystrobrevin and regulatory subunit of protein kinase A: a new role for dystrobrevin as a scaffold for signaling proteins. **2007**, 371, 1174-87 17

762 Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. **2007**, 26, 615-24 72

761 New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. **2007**, 13, 520-6 134

760 Morphological changes in the trigemino-rubral pathway in dystrophic (mdx) mice. **2007**, 416, 175-9 2

759 Correlations of Egen Klassifikation and Barthel Index scores with pulmonary function parameters in Duchenne muscular dystrophy. **2007**, 36, 132-9 11

758 Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. **2007**, 38, 1657-68 24

757 Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. **2007**, 171, 181-99 50

756 Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. **2007**, 171, 1180-8 49

755 The artificial 4-zinc-finger protein Bagly binds human utrophin promoter A at the endogenous chromosomal site and activates transcription. **2007**, 85, 358-65 14

754 Potential Mitigation of the Skeletal Complications of Duchenne Muscular Dystrophy with Vibration. **2007**,

753 Drosophila Dystrophin is required for integrity of the musculature. **2007**, 124, 617-30 27

752 Herpes simplex virus VP22 enhances adenovirus-mediated microdystrophin gene transfer to skeletal muscles in dystrophin-deficient (mdx) mice. **2007**, 18, 490-501 9

751 Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse. *PLoS ONE*, **2007**, 2, e427 3.7 7

750 Utrophin up-regulation by an artificial transcription factor in transgenic mice. *PLoS ONE*, **2007**, 2, e774 3.7 39

749 Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. **2007**, 117, 889-901 334

748 Altered biomechanical properties of carotid arteries in two mouse models of muscular dystrophy. **2007**, 103, 664-72 42

747	Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia. **2007**,		
746	Isotonic fatigue in laminin alpha2-deficient dy/dy dystrophic mouse diaphragm. **2007**, 36, 672-8		2
745	beta-dystrobrevin, a kinesin-binding receptor, interacts with the extracellular matrix components pancortins. **2007**, 85, 2631-9		21
744	Mechanosensitive channel properties and membrane mechanics in mouse dystrophic myotubes. **2007**, 581, 369-87		85
743	Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. **2007**, 5, 18		13
742	The dystrotelin, dystrophin and dystrobrevin superfamily: new paralogues and old isoforms. **2007**, 8, 19		38
741	Fetal muscle-derived cells can repair dystrophic muscles in mdx mice. *Experimental Cell Research*, **2007**, 313, 997-1007	4.2	8
740	Therapeutic approaches for muscle wasting disorders. **2007**, 113, 461-87		117
739	Syncoilin, an intermediate filament-like protein linked to the dystrophin associated protein complex in skeletal muscle. **2008**, 65, 2957-63		13
738	Analysis of skeletal muscle function in the C57BL6/SV129 syncoilin knockout mouse. **2008**, 19, 339-51		13
737	Changes in skeletal muscle expression of AQP1 and AQP4 in dystrophinopathy and dysferlinopathy patients. **2008**, 116, 235-46		22
736	Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study. **2008**, 129, 489-501		50
735	Increased expression of acetylcholine receptors in the diaphragm muscle of MDX mice. **2008**, 38, 1585-94		20
734	Kir4.1 and AQP4 associate with Dp71- and utrophin-DAPs complexes in specific and defined microdomains of Müller retinal glial cell membrane. **2008**, 56, 597-610		72
733	Full-length dystrophin gene transfer to the mdx mouse in utero. **2008**, 15, 531-6		30
732	Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype. **2008**, 7, 237-49		91
731	Components of the NGF signaling complex are altered in mdx mouse superior cervical ganglion and its target organs. *Neurobiology of Disease*, **2008**, 32, 402-11	7.5	9
730	Structural And Functional Organization Of The Synapse. **2008**,		3

729	[Cardiac involvement in Duchenne muscular dystrophy]. **2008**, 37, 648-53		2
728	alpha-Dystrobrevin isoforms differ in their colocalization with and stabilization of agrin-induced acetylcholine receptor clusters. **2008**, 154, 582-94		4
727	Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. *Neuromuscular Disorders*, **2008**, 18, 227-38	2.9	68
726	Mdx respiratory impairment following fibrosis of the diaphragm. *Neuromuscular Disorders*, **2008**, 18, 342-8	2.9	51
725	The detached locus encodes Drosophila Dystrophin, which acts with other components of the Dystrophin Associated Protein Complex to influence intercellular signalling in developing wing veins. **2008**, 313, 519-32		45
724	MicroRNA-206: the skeletal muscle-specific myomiR. **2008**, 1779, 682-91		295
723	Neuronal differentiation modulates the dystrophin Dp71d binding to the nuclear matrix. **2008**, 375, 303-7		13
722	Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. **2008**, 155, 574-84		81
721	Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan. **2008**, 173, 170-81		34
720	Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. **2008**, 19, 851-6		81
719	Encyclopedia of Neuroscience. **2008**, 929-1027		
718	The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. **2008**, 84, 431-53		96
717	Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging. **2008**, 49, 438-54		83
716	Laryngeal muscles are spared in the dystrophin deficient mdx mouse. **2008**, 51, 586-95		27
715	Deregulated protein kinase A signaling and myospryn expression in muscular dystrophy. **2008**, 283, 8070-4		45
714	The dystrophin Dp186 isoform regulates neurotransmitter release at a central synapse in Drosophila. **2008**, 28, 5105-14		23
713	Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. **2008**, 105, 7028-33		97
712	Nav1.4 deregulation in dystrophic skeletal muscle leads to Na+ overload and enhanced cell death. **2008**, 132, 199-208		46

711	Increased Gs signalling in platelets and impaired collagen activation, due to a defect in the dystrophin gene, result in increased blood loss during spinal surgery. **2008**, 17, 357-66		22
710	Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. **2008**, 295, C146-50		50
709	Gene expression in mouse brain following chronic hypoxia: role of sarcospan in glial cell death. **2008**, 32, 370-9		37
708	Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. **2008**, 27, 375-87		52
707	Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1. **2008**, 18, 842-50		28
706	Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. **2008**, 17, 3909-18		169
705	RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. **2008**, 17, 2622-32		35
704	Identification of duchenne muscular dystrophy female carriers by fluorescence in situ hybridization and RT-PCR. **2008**, 12, 221-3		6
703	Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). **2008**, 14, 853-61		55
702	Utrophins compensate for Dp71 absence in mdx3cv in adhered platelets. **2008**, 19, 39-47		4
701	Destabilization of the dystrophin-glycoprotein complex without functional deficits in alpha-dystrobrevin null muscle. *PLoS ONE*, **2008**, 3, e2604	3.7	16
700	Ectopic calcification is caused by elevated levels of serum inorganic phosphate in mdx mice. **2009**, 34, 77-88		22
699	Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping. **2009**, 2, 110-21		17
698	Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. **2009**, 106, 19023-8		158
697	Stra13 regulates oxidative stress mediated skeletal muscle degeneration. **2009**, 18, 4304-16		30
696	Rational design of antisense oligomers to induce dystrophin exon skipping. **2009**, 17, 1418-26		37
695	Chapter 2. Calcineurin signaling and the slow oxidative skeletal muscle fiber type. **2009**, 277, 67-101		20
694	Gene-mediated restoration of normal myofiber elasticity in dystrophic muscles. **2009**, 17, 19-25		40

693 Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. **2009**, 11, e28 64

692 Functional substitution by TAT-utrophin in dystrophin-deficient mice. **2009**, 6, e1000083 68

691 Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. **2009**, 296, C476-88 69

690 Interactions between connected half-sarcomeres produce emergent mechanical behavior in a mathematical model of muscle. **2009**, 5, e1000560 62

689 Protein O-mannosylation: conserved from bacteria to humans. **2009**, 19, 816-28 177

688 A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. **2009**, 18, 4405-14 119

687 Emerging strategies for cell and gene therapy of the muscular dystrophies. **2009**, 11, e18 56

686 Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. **2009**, 18, 2584-98 130

685 MALDI reveals membrane lipid profile reversion in MDX mice. *Neurobiology of Disease*, **2009**, 36, 252-8 7.5 28

684 Regulation of GABA(A) receptor membrane trafficking and synaptic localization. **2009**, 123, 17-31 45

683 Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice. **2009**, 212, 93-101 27

682 Muscular dystrophy with reduced beta-sarcoglycan in a cat. **2009**, 140, 278-82 10

681 Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions. **2009**, 583, 3600-4 53

680 PKA microdomain organisation and cAMP handling in healthy and dystrophic muscle in vivo. **2009**, 21, 819-26 19

679 Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. **2009**, 30, 22-8 36

678 Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. **2009**, 39, 239-43 39

677 By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. **2009**, 11, 46-56 40

676 Investigation of whole blood of SJL/J mice using neutron activation analysis. **2009**, 281, 97-99 8

675	Diverse roles of the actin cytoskeleton in striated muscle. **2009**, 30, 187-97		46
674	Specific knockdown of delta-sarcoglycan gene in C2C12 in vitro causes post-translational loss of other sarcoglycans without mechanical stress. **2009**, 323, 149-59		1
673	Dystroglycan glycosylation and muscular dystrophy. **2009**, 26, 349-57		21
672	Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. **2009**, 11, 40		48
671	A review of nutrition in Duchenne muscular dystrophy. **2009**, 22, 383-93		73
670	Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. **2009**, 15, 325-30		371
669	Stability and phase transitions in a mathematical model of Duchenne muscular dystrophy. **2009**, 260, 283-9		3
668	Abnormal glycosylation of dystroglycan in human genetic disease. **2009**, 1792, 853-61		62
667	RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. **2009**, 384, 322-8		8
666	Novel activation domain derived from Che-1 cofactor coupled with the artificial protein Jazz drives utrophin upregulation. *Neuromuscular Disorders*, **2009**, 19, 158-62	2.9	11
665	Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. **2009**, 1, 755-68		69
664	Oxidative stress regulation of stem and progenitor cells. **2009**, 11, 2777-89		138
663	Applications of metabolomics and proteomics to the mdx mouse model of Duchenne muscular dystrophy: lessons from downstream of the transcriptome. **2009**, 1, 32		35
662	Encyclopedia of Neuroscience. **2008**, 995-995		
661	The neurobiology of the dystrophin-associated glycoprotein complex. **2009**, 41, 344-59		99
660	Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. **2009**, 88, 502-22		61
659	High-frequency ultrasound to grade disease progression in murine models of Duchenne muscular dystrophy. **2009**, 28, 707-16		6
658	Muscular dystrophies: histology, immunohistochemistry, molecular genetics and management. **2010**, 16, 978-87		6

657	Abnormal distribution of sarcoglycan subcomplex in colonic smooth muscle cells of aganglionic bowel. **2010**, 25, 353-9	4
656	Differentiation of Human Embryonic Stem Cells to Cardiomyocytes. **2010**, 87-112	
655	C. elegans models of neuromuscular diseases expedite translational research. **2010**, 1,	13
654	Therapeutic targeting of signaling pathways in muscular dystrophy. **2010**, 88, 155-66	30
653	Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatment. **2010**, 339, 397-410	48
652	Gastric emptying, small intestinal transit and fecal output in dystrophic (mdx) mice. **2010**, 60, 75-9	29
651	The roles of the dystrophin-associated glycoprotein complex at the synapse. **2010**, 41, 1-21	103
650	CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres. **2010**, 31, 181-93	13
649	Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization. **2010**, 11, 345	20
648	Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. **2010**, 29, 391-8	49
647	Conformational dynamics of actin: effectors and implications for biological function. **2010**, 67, 609-29	36
646	A deficit of brain dystrophin 71 impairs hypothalamic osmostat. **2010**, 88, 324-34	13
645	Plakins in striated muscle. **2010**, 41, 299-308	26
644	Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice. **2010**, 41, 487-99	31
643	Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. **2010**, 42, 881-5	21
642	Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. **2010**, 28, 698-707	58
641	Induction of dystrophin Dp71 expression during neuronal differentiation: opposite roles of Sp1 and AP2alpha in Dp71 promoter activity. **2010**, 112, 474-85	16
640	Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. **2010**, 48, 282-289	119

639	Actin filaments and microtubule dual-granule transport in human adhered platelets: the role of alpha-dystrobrevins. **2010**, 149, 124-36		13
638	Catulin CTN-1 is required for BK channel subcellular localization in C. elegans body-wall muscle cells. **2010**, 29, 3184-95		22
637	Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene. **2010**, 17, 1355-62		29
636	Dysbindin-1, WAVE2 and Abi-1 form a complex that regulates dendritic spine formation. **2010**, 15, 976-86		73
635	Flightless flies: Drosophila models of neuromuscular disease. **2010**, 1184, e1-20		98
634	Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue. **2010**, 95, 641-56		54
633	Biochemical and molecular basis of muscle disease. 37-80		4
632	The Rap1 guanine nucleotide exchange factor C3G is required for preservation of larval muscle integrity in Drosophila melanogaster. *PLoS ONE*, **2010**, 5, e9403	3.7	12
631	The utrophin A 5'UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2. **2010**, 19, 1211-20		28
630	The interaction with HMG20a/b proteins suggests a potential role for beta-dystrobrevin in neuronal differentiation. **2010**, 285, 24740-50		20
629	The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. **2010**, 19, 752-60		28
628	Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases. **2010**, 2010, 740403		21
627	Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. **2010**, 123, 2008-13		68
626	Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates. **2010**, 107, 15069-74		57
625	Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies. **2010**, 2010, 849426		43
624	Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. **2010**, 18, 1675-82		33
623	Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. **2010**, 18, 1822-9		65
622	[Monogenetic dystonia: revisiting the dopaminergic hypothesis]. **2010**, 166, 389-99		3

621	Clinical outcomes after cardiac transplantation in muscular dystrophy patients. **2010**, 29, 432-8		74
620	Satellite cells are increasingly refractory to activation by nitric oxide and stretch in aged mouse-muscle cultures. **2010**, 42, 132-6		29
619	Phospholipase A2-derived lysophosphatidylcholine triggers Ca2+ entry in dystrophic skeletal muscle fibers. **2010**, 391, 401-6		18
618	A 3 months mild functional test regime does not affect disease parameters in young mdx mice. *Neuromuscular Disorders*, **2010**, 20, 273-80	2.9	34
617	Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes. **2010**, 21, 622-30		29
616	A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. **2010**, 11, 431-438		18
615	Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. **2010**, 176, 416-34		40
614	Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. **2010**, 176, 29-33		49
613	Genetic defects in muscular dystrophy. **2010**, 479, 291-322		21
612	Muscle Biophysics. **2010**,		7
611	The Genetics and Pathogenesis of Dystonia. **2010**, 34, 457-473		
610	Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. **2010**, 21, 221-37		32
609	Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of □1-syntrophin and □dystrobrevin in skeletal muscles of mdx mice. **2011**, 22, 1379-88		45
608	Translational Stem Cell Research. **2011**,		1
607	The biological role of the glycinergic synapse in early zebrafish motility. **2011**, 71, 1-11		7
606	Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. **2011**, 107 Suppl, S80-93		37
605	Pre-clinical study of 21 approved drugs in the mdx mouse. *Neuromuscular Disorders*, **2011**, 21, 313-27	2.9	18
604	Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. **2011**, 96, 167-201		122

603	Peptide-based inhibition of NF-B rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. **2011**, 17, 508-15		47
602	Knockdown of dystrophin Dp71 impairs PC12 cells cycle: localization in the spindle and cytokinesis structures implies a role for Dp71 in cell division. *PLoS ONE*, **2011**, 6, e23504	3.7	29
601	Immune response and mitochondrial metabolism are commonly deregulated in DMD and aging skeletal muscle. *PLoS ONE*, **2011**, 6, e26952	3.7	28
600	Characterization of Dp71(78-79), a novel dystrophin mutant that stimulates PC12 cell differentiation. **2011**, 119, 697-707		13
599	Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy. **2011**, 51, 163-71		43
598	Increased catalase expression improves muscle function in mdx mice. **2011**, 96, 194-202		38
597	Distribution of dystrophin- and utrophin-associated protein complexes (DAPC/UAPC) in human hematopoietic stem/progenitor cells. **2011**, 87, 312-22		7
596	BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. *Neurobiology of Disease*, **2011**, 41, 353-60	7.5	28
595	Lack of dystrophin functionally affects B2/4-nicotinic acethylcholine receptors in sympathetic neurons of dystrophic mdx mice. *Neurobiology of Disease*, **2011**, 41, 528-37	7.5	6
594	Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse. *Neurobiology of Disease*, **2011**, 43, 558-64	7.5	28
593	Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster. **2011**, 353, 275-81		3
592	Expression of dystrophins and the dystrophin-associated-protein complex by pituicytes in culture. **2011**, 36, 1407-16		5
591	Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. **2011**, 12, 127		13
590	Improvement of cardiac contractile function by peptide-based inhibition of NF-B in the utrophin/dystrophin-deficient murine model of muscular dystrophy. *Journal of Translational Medicine*, **2011**, 9, 68	8.5	33
589	Aberrant repair and fibrosis development in skeletal muscle. **2011**, 1, 21		486
588	Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. **2011**, 26, 1935-8		26
587	Psychiatric disorders, myoclonus dystonia, and the epsilon-sarcoglycan gene: a systematic review. **2011**, 26, 1939-42		31
586	Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinsonˆs disease. **2011**, 26, 1943-7		37

585	Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation. **2011**, 26, 1931-4	38
584	Hindlimb skeletal muscle function in myostatin-deficient mice. **2011**, 43, 49-57	44
583	An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. **2011**, 44, 563-70	21
582	Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. **2011**, 13, 497-506	43
581	Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. **2011**, 71, 982-1005	106
580	A gain-of-glycosylation mutation associated with myoclonus-dystonia syndrome affects trafficking and processing of mouse ε-sarcoglycan in the late secretory pathway. **2011**, 32, 1246-58	19
579	Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy. **2011**, 44, 853-8	31
578	Rescue from respiratory dysfunction by transduction of full-length dystrophin to diaphragm via the peritoneal cavity in utrophin/dystrophin double knockout mice. **2011**, 19, 1230-5	11
577	TAT-Utrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice. **2011**, 111, 200-5	20
576	NF-κB signaling in skeletal muscle health and disease. **2011**, 96, 85-119	80
575	Regulation of the cardiac sodium channel Nav1.5 by utrophin in dystrophin-deficient mice. **2011**, 89, 320-8	33
574	SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes. **2011**, 108, 294-304	178
573	Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. **2011**, 20, 3478-93	124
572	Dysbindin-containing complexes and their proposed functions in brain: from zero to (too) many in a decade. **2011**, 3,	50
571	Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. **2011**, 108, 762-7	108
570	Internal deletion compromises the stability of dystrophin. **2011**, 20, 2955-63	32
569	Disruption of muscle renin-angiotensin system in AT1a-/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury. **2012**, 303, R321-31	12
568	Muscular dystrophies at different ages: metabolic and endocrine alterations. **2012**, 2012, 485376	32

567	Elastic energy storage and radial forces in the myofilament lattice depend on sarcomere length. **2012**, 8, e1002770		27
566	Dp71 gene disruption alters the composition of the dystrophin-associated protein complex and neuronal nitric oxide synthase expression in the hypothalamic supraoptic and paraventricular nuclei. **2012**, 213, 239-49		12
565	Glycoproteomic characterization of recombinant mouse □-dystroglycan. **2012**, 22, 662-75		45
564	□1D chain increases □7□1 integrin and laminin and protects against sarcolemmal damage in mdx mice. **2012**, 21, 1592-603		27
563	Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. **2012**, 20, 1222-33		90
562	Evidence TRPV4 contributes to mechanosensitive ion channels in mouse skeletal muscle fibers. **2012**, 6, 246-54		41
561	Increased resting intracellular calcium modulates NF-B-dependent inducible nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes. **2012**, 287, 20876-87		63
560	Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases. **2012**, 53, 4-27		38
559	Prednisolone treatment does not interfere with 2N-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. **2012**, 23, 262-73		10
558	Store-operated Ca2+ entry (SOCE) pathways. **2012**,		1
557	Expression of sarcoglycans in the human cerebral cortex: an immunohistochemical and molecular study. **2012**, 196, 470-80		6
556	Sarcoplasmic reticulum Ca2+ permeation explored from the lumen side in mdx muscle fibers under voltage control. **2012**, 139, 209-18		23
555	Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. *Science Translational Medicine*, **2012**, 4, 162ra155	17.5	74
554	Electrical stimulation induces calcium-dependent up-regulation of neuregulin-1□in dystrophic skeletal muscle cell lines. **2012**, 29, 919-30		15
553	Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. **2012**, 12, 139-51		25
552	Losartan enhances the success of myoblast transplantation. **2012**, 21, 139-52		27
551	Overview on DMD exon skipping. **2012**, 867, 97-116		39
550	Lack of dystrophin in mdx mice modulates the expression of genes involved in neuron survival and differentiation. **2012**, 35, 691-701		10

549	Persistent activation of omentum influences the pattern of muscular lesion in the mdx diaphragm. **2012**, 350, 77-88		6
548	Nutrition strategies to improve physical capabilities in Duchenne muscular dystrophy. **2012**, 23, 187-99, xii-xiii		13
547	Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice. **2012**, 23, 1269-79		25
546	Efficient TALEN-mediated gene knockout in livestock. **2012**, 109, 17382-7		456
545	Supersonic shear imaging provides a reliable measurement of resting muscle shear elastic modulus. **2012**, 33, N19-28		158
544	Carence en tissu osseux et en dystrophine musculaire chez la souris mdx. **2012**, 79, 206-211		
543	A single 30 min treadmill exercise session is suitable for proof-of concept studies in adult mdx mice: a comparison of the early consequences of two different treadmill protocols. *Neuromuscular Disorders*, **2012**, 22, 170-82	2.9	48
542	Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies. *Neuromuscular Disorders*, **2012**, 22, 34-42	2.9	29
541	Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. *Neuromuscular Disorders*, **2012**, 22, 418-26	2.9	17
540	The dystrophin-glycoprotein complex in brain development and disease. **2012**, 35, 487-96		129
539	Dynamic of ion channel expression at the plasma membrane of cardiomyocytes. *Physiological Reviews*, **2012**, 92, 1317-58	47.9	76
538	Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design. **2012**, 420, 87-98		17
537	Alpha-Dystrobrevin and its associated proteins in human promyelocytic leukemia cells induced to apoptosis. **2012**, 75, 3291-303		10
536	Partial opening and subconductance gating of mechanosensitive ion channels in dystrophic skeletal muscle. **2012**, 590, 6167-85		9
535	Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. *Orphanet Journal of Rare Diseases*, **2012**, 7, 45	4.2	37
534	Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. **2012**, 2, 16		64
533	Phosphorylation on threonine 11 of □-dystrobrevin alters its interaction with kinesin heavy chain. **2012**, 279, 4131-44		2
532	Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. **2012**, 20, 2134-42		37

531	Quantitative changes of nicotinic receptors in the hippocampus of dystrophin-deficient mice. **2012**, 1483, 96-104		14
530	TRP channels in normal and dystrophic skeletal muscle. **2012**, 12, 326-34		40
529	The N-terminal actin-binding tandem calponin-homology (CH) domain of dystrophin is in a closed conformation in solution and when bound to F-actin. **2012**, 103, 1970-8		19
528	Cell-Based Therapies in Skeletal Muscle Disease. **2012**, 1053-1063		
527	Nesprin interchain associations control nuclear size. **2012**, 69, 3493-509		70
526	The crystal structures of dystrophin and utrophin spectrin repeats: implications for domain boundaries. *PLoS ONE*, **2012**, 7, e40066	3.7	22
525	Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine. *PLoS ONE*, **2012**, 7, e49346	3.7	24
524	Exon Skipping and Myoblast Transplantation: Single or Combined Potential Options for Treatment of Duchenne Muscular Dystrophy. **2012**,		
523	Duchenne Muscular Dystrophy and Brain Function. **2012**,		1
522	Cell-matrix interactions in muscle disease. **2012**, 226, 200-18		64
521	Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin. **2012**, 80, 1377-92		14
520	Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. **2012**, 484, 394-8		196
519	Progress in gene therapy of dystrophic heart disease. **2012**, 19, 678-85		27
518	Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle. **2012**, 11, 4413-24		36
517	Cellular mechanism underlying the facilitation of contractile response of vas deferens smooth muscle by sodium orthovanadate. **2012**, 366, 149-57		2
516	Application of complementary luminescent and fluorescent imaging techniques to visualize nuclear and cytoplasmic Ca□+ signalling during the in vivo differentiation of slow muscle cells in zebrafish embryos under normal and dystrophic conditions. **2012**, 39, 78-86		11
515	Bone tissue and muscle dystrophin deficiency in mdx mice. **2012**, 79, 129-33		9
514	Stressing caveolae new role in cell mechanics. **2012**, 22, 381-9		95

513	Deletion of aquaporin-4 changes the perivascular glial protein scaffold without disrupting the brain endothelial barrier. **2012**, 60, 432-40	38
512	Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene. **2012**, 45, 43-60	80
511	Elemental analysis of biological tissues of animal models in muscular dystrophies investigation. **2012**, 291, 373-378	5
510	Glycomimetic affinity-enrichment proteomics identifies partners for a clinically-utilized iminosugar. **2013**, 4, 3442-3446	7
509	Linking cytoarchitecture to metabolism: sarcolemma-associated plectin affects glucose uptake by destabilizing microtubule networks in mdx myofibers. **2013**, 3, 14	22
508	Elemental analysis of biological tissues of Dmdmdx/J and C57BL/6J mice strains investigated by neutron activation analysis. **2013**, 296, 579-584	2
507	Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy. **2013**, 70, 407-23	25
506	UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation. **2013**, 14, 3	12
505	Progressive muscular dystrophies. **2013**, 113, 1343-66	16
504	Wasting mechanisms in muscular dystrophy. **2013**, 45, 2266-79	91
503	Protective effect of melatonin on TNF-□nduced muscle atrophy in L6 myotubes. **2013**, 54, 417-25	13
502	AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy. **2013**, 19, 614-24	34
501	A Laboratory for Education in Molecular Medicine: a Dedicated Resource for Medical Student Research. **2013**, 23, 108-118	0
500	Altered functional differentiation of mesoangioblasts in a genetic myopathy. **2013**, 17, 419-28	3
499	A new look at cytoskeletal NOS-1 and □-dystroglycan changes in developing muscle and brain in control and mdx dystrophic mice. **2013**, 242, 1369-81	13
498	From chaos to split-ups--SHG microscopy reveals a specific remodelling mechanism in ageing dystrophic muscle. **2013**, 229, 477-85	20
497	Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers. **2013**, 33, 1174-213	43
496	Duchenne Muscular Dystrophy. **2013**, 421-424	0

495	Novel mutation in exon 56 of the dystrophin gene in a child with Duchenne muscular dystrophy. **2013**, 32, 1166-70		4
494	Hydroximic acid derivatives: pleiotropic HSP co-inducers restoring homeostasis and robustness. **2013**, 19, 309-46		48
493	SGCE mutations cause psychiatric disorders: clinical and genetic characterization. **2013**, 136, 294-303		72
492	Alpha 7 integrin preserves the function of the extensor digitorum longus muscle in dystrophin-null mice. **2013**, 115, 1388-92		10
491	Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy. **2014**, 7, 41-54		45
490	Functional muscle ischemia in Duchenne and Becker muscular dystrophy. **2013**, 4, 381		52
489	Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. **2013**, 22, 4368-82		94
488	Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice. **2013**, 114, 482-9		11
487	Cellular Transplantation Alters the Disease Progression in Becker's Muscular Dystrophy. **2013**, 2013, 909328		7
486	Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy. **2013**, 110, 19024-9		20
485	Identification of DMD Mutation in Korean Siblings Using Full Gene Sequencing. **2013**, 13, 127-130		
484	Molecular imaging to target transplanted muscle progenitor cells. **2013**,		3
483	Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice. *PLoS ONE*, **2013**, 8, e69194	3.7	19
482	Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. *PLoS ONE*, **2013**, 8, e72121	3.7	52
481	Genetic Diseases Associated with Protein Glycosylation Disorders in Mammals. **2013**,		2
480	Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of duchenne muscular dystrophy by immunostaining and western blot. *PLoS ONE*, **2014**, 9, e88280	3.7	17
479	Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of duchenne muscular dystrophy. *PLoS ONE*, **2014**, 9, e89277	3.7	37
478	Degeneration of neuromuscular junction in age and dystrophy. **2014**, 6, 99		106

477	Whole body periodic acceleration is an effective therapy to ameliorate muscular dystrophy in mdx mice. *PLoS ONE*, **2014**, 9, e106590	3.7	18
476	Gene expression profiling of Duchenne muscular dystrophy reveals characteristics along disease progression. **2014**, 13, 1402-11		8
475	Advanced Skeletal Muscle MR Imaging Approaches in the Assessment of Muscular Dystrophies. **2014**, 02,		3
474	Pharmacological Interventions of Selenium in Duchene Muscular Dystrophy: The Role of Reactive Oxygen Species in Mediating Lipid Peroxide Formation. **2014**,		
473	Microtubule binding distinguishes dystrophin from utrophin. **2014**, 111, 5723-8		87
472	SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. **2014**, 261, 2296-304		42
471	Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy. **2014**, 9, 210		5
470	Dysregulation of calcium homeostasis in muscular dystrophies. **2014**, 16, e16		60
469	Rapid depletion of muscle progenitor cells in dystrophic mdx/utrophin-/- mice. **2014**, 23, 4786-800		38
468	Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models. **2014**, 28, 2603-19		11
467	Terminal Schwann cells participate in neuromuscular synapse remodeling during reinnervation following nerve injury. **2014**, 34, 6323-33		80
466	Compared with that of MUFA, a high dietary intake of n-3 PUFA does not reduce the degree of pathology in mdx mice. **2014**, 111, 1791-800		9
465	The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice. **2014**, 3, e148		21
464	Targeting TGF-Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-Type I Receptor. **2014**, 3, e156		23
463	Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment. **2014**, 28, 1593-9		47
462	Inhibition of autoimmune Chagas-like heart disease by bone marrow transplantation. **2014**, 8, e3384		5
461	Molecular and cell-based therapies for muscle degenerations: a road under construction. **2014**, 5, 119		50
460	Adipose tissue-derived stem cell secreted IGF-1 protects myoblasts from the negative effect of myostatin. **2014**, 2014, 129048		16

459	Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy. **2014**,	3
458	Myofibrillar misalignment correlated to triad disappearance of mdx mouse gastrocnemius muscle probed by SHG microscopy. **2014**, 5, 858-75	8
457	New insights on contraction efficiency in patients with Duchenne muscular dystrophy. **2014**, 117, 658-62	17
456	-Syntrophin-deficient mice exhibit impaired muscle force recovery after osmotic shock. **2014**, 49, 728-35	4
455	Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice. **2014**, 229, 1283-91	21
454	Do not know where to press? Cricoid pressure in the very young. **2014**, 31, 333-4	4
453	Duchenne muscular dystrophy and malignant hyperthermia: a genetic study of the ryanodine receptor in 47 patients. **2014**, 31, 341-2	2
452	Intrathecal baclofen toxicity: an unusual cause of paediatric postoperative coma and respiratory depression. **2014**, 31, 334-6	3
451	Calpain-mediated proteolysis of tropomodulin isoforms leads to thin filament elongation in dystrophic skeletal muscle. **2014**, 25, 852-65	24
450	Resveratrol improves muscle function but not oxidative capacity in young mdx mice. **2014**, 92, 243-51	34
449	Dystrophin Analysis in Clinical Trials. **2014**, 1, 41-53	16
448	Anaesthesia for orphan disease: Haddad syndrome (Ondine-Hirschsprung disease). **2014**, 31, 338-40	3
447	Glycosaminoglycan modifications in Duchenne muscular dystrophy: specific remodeling of chondroitin sulfate/dermatan sulfate. **2014**, 73, 789-97	13
446	Anaesthesia for orphan disease: combined spinal-epidural anaesthesia in a patient with Friedreich's ataxia. **2014**, 31, 340-1	0
445	Anaesthesia for orphan disease: management of an infant with Silver-Russell syndrome. **2014**, 31, 336-8	0
444	A mathematical model of skeletal muscle disease and immune response in the mdx mouse. **2014**, 2014, 871810	7
443	Duchenne/Becker muscular dystrophy: A report on clinical, biochemical, and genetic study in Gujarat population, India. **2014**, 17, 303-7	9
442	Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. **2014**, 23, 618-36	10

441	Description of a utrophin associated protein complex in lipid raft domains of human artery smooth muscle cells. **2014**, 1838, 1047-54		5
440	Altered acetylcholine release in the hippocampus of dystrophin-deficient mice. **2014**, 269, 173-83		11
439	New developments in exon skipping and splice modulation therapies for neuromuscular diseases. **2014**, 14, 809-19		53
438	Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization. **2014**, 205, 377-93		45
437	The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. **2014**, 28, 548-68		54
436	Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling. **2014**, 23, 1237-49		122
435	Dystrophin complex functions as a scaffold for signalling proteins. **2014**, 1838, 635-42		118
434	Use of in silico tools for classification of novel missense mutations identified in dystrophin gene in developing countries. **2014**, 535, 250-4		6
433	Utrophin regulates modal gating of mechanosensitive ion channels in dystrophic skeletal muscle. **2014**, 592, 3303-23		5
432	The actin binding affinity of the utrophin tandem calponin-homology domain is primarily determined by its N-terminal domain. **2014**, 53, 1801-9		17
431	Genetic correction using engineered nucleases for gene therapy applications. **2014**, 56, 63-77		34
430	Perturbation of the monomer-monomer interfaces of the benzoylformate decarboxylase tetramer. **2014**, 53, 4358-67		4
429	When a mid-intronic variation of DMD gene creates an ESE site. *Neuromuscular Disorders*, **2014**, 24, 1111-79		22
428	Absence of δ-sarcoglycan alters the response of p70S6 kinase to mechanical perturbation in murine skeletal muscle. **2014**, 4, 13		11
427	Arginine butyrate per os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability. *Neurobiology of Disease*, **2014**, 71, 325-33	7.5	7
426	Age-dependent changes in diastolic Ca(2+) and Na(+) concentrations in dystrophic cardiomyopathy: Role of Ca(2+) entry and IP3. **2014**, 452, 1054-9		29
425	Golgi phosphoprotein 3 mediates the Golgi localization and function of protein O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1. **2014**, 289, 14762-70		36
424	De novo mutation in DMD gene in a patient with combined hemophilia A and Duchenne muscular dystrophy. **2014**, 99, 184-7		3

423	Skeletal muscle satellite cells: mediators of muscle growth during development and implications for developmental disorders. **2014**, 50, 723-32		55
422	Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. **2014**, 22, 1333-1341		40
421	Muscular dystrophy in a dog resembling human becker muscular dystrophy. **2014**, 150, 429-33		11
420	Nucleocytoplasmic shuttling of the Duchenne muscular dystrophy gene product dystrophin Dp71d is dependent on the importin β1 and CRM1 nuclear transporters and microtubule motor dynein. **2014**, 1843, 985-1001		17
419	The miRNA-mediated cross-talk between transcripts provides a novel layer of posttranscriptional regulation. **2014**, 85, 149-99		26
418	Conserved regions of the DMD 3′UTR regulate translation and mRNA abundance in cultured myotubes. *Neuromuscular Disorders*, **2014**, 24, 693-706	2.9	3
417	Complete restoration of multiple dystrophin isoforms in genetically corrected Duchenne muscular dystrophy patient-derived cardiomyocytes. **2014**, 1, 1		28
416	Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. **2014**, 2, 11		27
415	Assessing functional performance in the mdx mouse model. **2014**,		80
414	Microfluidic-assisted cyclic mechanical stimulation affects cellular membrane integrity in a human muscular dystrophy in vitro model. **2015**, 5, 98429-98439		18
413	Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. *Scientific Reports*, **2015**, 5, 12831	4.9	70
412	Increased calcium in neurons in the cerebral cortex and cerebellum is not associated with cell loss in the mdx mouse model of Duchenne muscular dystrophy. **2015**, 26, 785-90		7
411	Interdomain Linker Determines Primarily the Structural Stability of Dystrophin and Utrophin Tandem Calponin-Homology Domains Rather than Their Actin-Binding Affinity. **2015**, 54, 5480-8		10
410	Involvement of adiponectin in the pathogenesis of dystrophinopathy. **2015**, 5, 25		33
409	Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells. **2015**, 5, 40		21
408	Prenatal muscle development in a mouse model for the secondary dystroglycanopathies. **2016**, 6, 3		3
407	Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. **2015**, 2, 343-355		9
406	Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. **2015**, 20, 8823-55		53

405	A TALEN-Exon Skipping Design for a Bethlem Myopathy Model in Zebrafish. *PLoS ONE*, **2015**, 10, e0133986	17
404	Dystrophin induced cognitive impairment: mechanisms, models and therapeutic strategies. **2015**, 22, 108-18	19
403	Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. **2015**, 24, 1243-55	37
402	A possible role of dystrophin in neuronal excitability: a review of the current literature. **2015**, 51, 255-62	39
401	Regulation of skeletal muscle development and disease by microRNAs. **2015**, 56, 165-90	13
400	Drug Discovery of Therapies for Duchenne Muscular Dystrophy. **2015**, 20, 1189-203	13
399	EF-hand domains are involved in the differential cellular distribution of dystrophin Dp40. **2015**, 600, 115-20	6
398	Ultra-structural time-course study in the C. elegans model for Duchenne muscular dystrophy highlights a crucial role for sarcomere-anchoring structures and sarcolemma integrity in the earliest steps of the muscle degeneration process. **2015**, 24, 6428-45	19
397	The N- and C-Terminal Domains Differentially Contribute to the Structure and Function of Dystrophin and Utrophin Tandem Calponin-Homology Domains. **2015**, 54, 6942-50	3
396	[Duchenne muscular dystrophy pathophysiology]. **2015**, 22, 12S18-23	2
395	Identification and computational analysis of gene regulatory elements. **2015**, 2015, pdb.top083642	4
394	Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications. **2015**, 1852, 732-41	47
393	Flexibility in the N-terminal actin-binding domain: clues from in silico mutations and molecular dynamics. **2015**, 83, 696-710	6
392	The sleep characteristics in symptomatic patients with Duchenne muscular dystrophy. **2015**, 19, 1051-6	16
391	The role of proteases in excitation-contraction coupling failure in muscular dystrophy. **2015**, 308, C33-40	9
390	SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor □ **2015**, 116, 1880-7	19
389	Generation of muscular dystrophy model rats with a CRISPR/Cas system. *Scientific Reports*, **2014**, 4, 5635[illegible]4.9	90
388	Pre-exercise low-level laser therapy improves performance and levels of oxidative stress markers in mdx mice subjected to muscle fatigue by high-intensity exercise. **2015**, 30, 1719-27	18

387	Role of gelatinases in pathological and physiological processes involving the dystrophin-glycoprotein complex. **2015**, 44-46, 130-7		13
386	Localization of Dystrobrevin in Cajal Bodies and Nucleoli: A New Role for Dystrobrevin in the Structure/Stability of the Nucleolus. **2015**, 116, 2755-65		3
385	Altered ROS production, NF-B activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells. **2015**, 1852, 1410-9		33
384	Lipogenesis mitigates dysregulated sarcoplasmic reticulum calcium uptake in muscular dystrophy. **2015**, 1851, 1530-8		12
383	Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice. **2015**, 4, e255		23
382	Compartment syndrome in Duchenne muscular dystrophy. **2015**, 12, 203-205		0
381	Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. **2015**, 8, 195-213		264
380	Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. **2015**, 355, 329-40		81
379	Branched Chain Amino Acids in Inherited Muscle Disease: The Case of Duchenne Muscular Dystrophy. **2015**, 277-287		
378	Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice. **2015**, 33, 962-75		17
377	Branched Chain Amino Acids in Clinical Nutrition. **2015**,		4
376	Emerging Gene Correction Strategies for Muscular Dystrophies: Scientific Progress and Regulatory Impact. **2016**,		
375	Dystrophin Is Required for Proper Functioning of Luminance and Red-Green Cone Opponent Mechanisms in the Human Retina. **2016**, 57, 3581-7		8
374	Fast detection of deletion breakpoints using quantitative PCR. **2016**, 39, 365-9		1
373	Duchenne muscular dystrophy in the Western Cape, South Africa: Where do we come from and where are we going?. **2016**, 106, S67-71		3
372	Therapeutic Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist, on CCl Induced Skeletal Muscle Injury. *International Journal of Molecular Sciences*, **2016**, 17, 227	6.3	14
371	Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and Disease. **2015**, 6, 420		43
370	Obesity and Premature Loss of Mobility in Two Adolescents with Becker Muscular Dystrophy After HeartMate II Implantation. **2016**, 62, e5-7		7

369	Cognitive flexibility deficits in a mouse model for the absence of full-length dystrophin. **2016**, 15, 558-67		20
368	Twenty-year follow-up of newborn screening for patients with muscular dystrophy. **2016**, 53, 570-8		24
367	Noncoding RNAs in the regulation of skeletal muscle biology in health and disease. **2016**, 94, 853-66		43
366	Dilated cardiomyopathy mutations in □sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability. **2016**, 310, H1140-50		8
365	Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods. **2016**, 3, 77-90		12
364	Care of Adults with Chronic Childhood Conditions. **2016**,		4
363	CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies. *Neuromuscular Disorders*, **2016**, 26, 504-10	2.9	27
362	Noncoding RNAs and Duchenne muscular dystrophy. **2016**, 8, 1527-1537		18
361	Impact of P2RX7 ablation on the morphological, mechanical and tissue properties of bones in a murine model of duchenne muscular dystrophy. **2016**, 49, 3444-3451		5
360	Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules. **2016**, 116, 1304-15		26
359	Genome- and Cell-Based Strategies in Therapy of Muscular Dystrophies. **2016**, 81, 678-90		3
358	Age-related alterations in the sarcolemmal environment are attenuated by lifelong caloric restriction and voluntary exercise. **2016**, 83, 148-57		14
357	Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy. **2016**, 1,		30
356	Characterization of a Dmd (EGFP) reporter mouse as a tool to investigate dystrophin expression. **2016**, 6, 25		14
355	A dynamic trinucleotide repeat (TNR) expansion in the DMD gene. **2016**, 30, 254-260		1
354	BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. **2016**, 186, 3246-3260		19
353	Dystrophin expression in an Egyptian family suffering from muscular dystrophy. **2016**, 36, 61-65		
352	Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. **2016**, 43, 1623-35		44

351	Single-walled carbon nanotubes affect the expression of the CCND2 gene in human U87 glioma cells. **2016**, 47, 180-188		5
350	Isolation and characterization of neural stem cells from dystrophic mdx mouse. *Experimental Cell Research*, **2016**, 343, 190-207	4.2	9
349	Reactive oxygen species and calcium signals in skeletal muscle: A crosstalk involved in both normal signaling and disease. **2016**, 60, 172-9		40
348	Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis. **2016**, 73, 2583-99		27
347	Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. *Physiological Reviews*, **2016**, 96, 253-305	47.9	217
346	Regenerative Medicine for Degenerative Muscle Diseases. **2016**,		
345	Practical Nutrition Guidelines for Individuals with Duchenne Muscular Dystrophy. **2016**, 225-279		1
344	Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice. **2016**, 75, 313-326		17
343	Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles. **2016**, 25, 24-43		20
342	Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis. **2016**, 16, 345-66		30
341	CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. **2016**, 24, 564-9		163
340	Identification of Dp71 Isoforms Expressed in PC12 Cells: Subcellular Localization and Colocalization with □-Dystroglycan and □-Syntrophin. **2016**, 58, 201-9		11
339	Genetic studies of alcohol dependence in the context of the addiction cycle. **2017**, 122, 3-21		98
338	Functional validation and expression analysis of myotubes converted from skin fibroblasts using a simple direct reprogramming strategy. **2017**, 6, 9-15		4
337	Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. **2017**, 1, CD010899		25
336	Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations. **2017**, 312, C209-C221		15
335	Genome and Transcriptome Assembly of the Canadian Beaver (). **2017**, 7, 755-773		13
334	The Plasticity of Skeletal Muscle. **2017**,		

333	NGF-dependent axon growth and regeneration are altered in sympathetic neurons of dystrophic mdx mice. **2017**, 80, 1-17	11
332	Pharmacological advances for treatment in Duchenne muscular dystrophy. **2017**, 34, 36-48	95
331	Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy. **2017**, 187, 1577-1585	12
330	Overview of the Muscle Cytoskeleton. **2017**, 7, 891-944	97
329	SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells. **2017**, 26, 3342-3351	13
328	Spatial distribution and molecular dynamics of dystrophin glycoprotein components at the neuromuscular junction. **2017**, 130, 1752-1759	7
327	Muscle and Limb Mechanics. **2017**, 7, 429-462	5
326	Axonal domain disorganization in Caspr1 and Caspr2 mutant myelinated axons affects neuromuscular junction integrity, leading to muscle atrophy. **2017**, 95, 1373-1390	12
325	Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles. **2017**, 24, 113-119	3
324	Interleukin-6 and neuregulin-1 as regulators of utrophin expression via the activation of NRG-1/ErbB signaling pathway in mdx cells. **2017**, 1863, 770-780	3
323	Genetic ablation of P65 subunit of NF-Ƀ in mdx mice to improve muscle physiological function. **2017**, 56, 759-767	7
322	Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. **2017**, 45, 961-976	29
321	Altered Biological Properties in Dp71 Over-Expressing HBE Cells. **2017**, 43, 2022-2036	4
320	Effects of (-)-epicatechin on frontal cortex DAPC and dysbindin of the mdx mice. **2017**, 658, 142-149	3
319	Biochemistry, Cytogenetics and DMD Gene Mutations in South Indian Patients with Duchenne Muscular Dystrophy. **2017**, 17, 126-134	
318	Effects of omega-3 on matrix metalloproteinase-9, myoblast transplantation and satellite cell activation in dystrophin-deficient muscle fibers. **2017**, 369, 591-602	5
317	MLPA identification of dystrophin mutations and in silico evaluation of the predicted protein in dystrophinopathy cases from India. **2017**, 18, 67	14
316	Fibrosis, low vascularity, and fewer slow fibers after rotator-cuff injury. **2017**, 55, 715-726	20

315	The role of laminins in the organization and function of neuromuscular junctions. **2017**, 57-58, 86-105		48
314	Retinoid acid-induced microRNA-27b-3p impairs C2C12 myoblast proliferation and differentiation by suppressing dystrobrevin. *Experimental Cell Research*, **2017**, 350, 301-311	4.2	12
313	Small molecule adiponectin receptor agonist GTDF protects against skeletal muscle atrophy. **2017**, 439, 273-285		19
312	Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study. **2017**, 4, 217-236		5
311	Skeletal muscle-derived interstitial progenitor cells (PICs) display stem cell properties, being clonogenic, self-renewing, and multi-potent in vitro and in vivo. **2017**, 8, 158		20
310	Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy. **2017**, 2, 47		3
309	Tempol Supplementation Restores Diaphragm Force and Metabolic Enzyme Activities in mdx Mice. **2017**, 6,		14
308	Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies. **2017**, 8,		13
307	Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. **2017**, 2017, 8765154		23
306	Bridging the Gap: An Osteopathic Primary Care-Centered Approach to Duchenne Muscular Dystrophy. **2017**, 117, 377-385		1
305	Basics of Skeletal Muscle Function and Normal Physiology. **2017**, 21-38		2
304	Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Confirmed by Multiplex Ligation-Dependent Probe Amplification: Genotype-Phenotype Correlation in a Large Cohort. **2017**, 13, 91-97		29
303	Deregulation of Nrf2/ARE signaling pathway causes susceptibility of dystrophin-deficient myotubes to menadione-induced oxidative stress. *Experimental Cell Research*, **2018**, 364, 224-233	4.2	4
302	Humanizing the mdx mouse model of DMD: the long and the short of it. **2018**, 3, 4		52
301	Sertoli cells for cell transplantation: pre-clinical studies and future perspectives. **2018**, 6, 385-395		25
300	Collagen XIII Is Required for Neuromuscular Synapse Regeneration and Functional Recovery after Peripheral Nerve Injury. **2018**, 38, 4243-4258		23
299	Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. *Neuromuscular Disorders*, **2018**, 28, 427-442	2.9	9
298	Brain-related comorbidities in boys and men with Duchenne Muscular Dystrophy: A descriptive study. **2018**, 22, 488-497		19

297	Cellular Biomechanics in Skeletal Muscle Regeneration. **2018**, 126, 125-176		21
296	The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. **2018**, 6, 259-271		4
295	p110 of PI3K is necessary and sufficient for quiescence exit in adult muscle satellite cells. **2018**, 37,		17
294	From excitation to intracellular Ca movements in skeletal muscle: Basic aspects and related clinical disorders. *Neuromuscular Disorders*, **2018**, 28, 394-401	2.9	19
293	Dysregulation of Intracellular Ca in Dystrophic Cortical and Hippocampal Neurons. **2018**, 55, 603-618		15
292	ABC of multifaceted dystrophin glycoprotein complex (DGC). **2018**, 233, 5142-5159		12
291	Dystrophin Dp71 Isoforms Are Differentially Expressed in the Mouse Brain and Retina: Report of New Alternative Splicing and a Novel Nomenclature for Dp71 Isoforms. **2018**, 55, 1376-1386		20
290	Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients With Duchenne Muscular Disease. **2018**, 58, 314-326		16
289	Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. **2018**, 26, 132-147		15
288	Application of Multiplex PCR for Detection of Duchunne Muscular Dystrophy: A Childhood Neuromuscular Disorder. **2018**, 09,		
287	Muscle strength deficiency and mitochondrial dysfunction in a muscular dystrophy model of and its functional response to drugs. **2018**, 11,		25
286	Automated muscle histopathology analysis using CellProfiler. **2018**, 8, 32		19
285	Effects and Mechanisms of Taurine as a Therapeutic Agent. **2018**, 26, 225-241		119
284	Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine. **2018**, 7,		12
283	Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. *Nature Communications*, **2018**, 9, 3950	17.4	24
282	Significant Association Between Variant in SGCD and Age-Related Macular Degeneration. **2018**, 9,		2
281	Genetics. **2018**, 125-189		
280	Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD. **2019**, 28, 307-319		18

279	IP receptor blockade restores autophagy and mitochondrial function in skeletal muscle fibers of dystrophic mice. **2018**, 1864, 3685-3695		15
278	GsMTx4-D provides protection to the D2.mdx mouse. *Neuromuscular Disorders*, **2018**, 28, 868-877	2.9	7
277	Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2. **2018**, 596, 5175-5197		11
276	Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy. **2018**, 174, 67-78		69
275	Biochemical and Functional Interplay Between Ion Channels and the Components of the Dystrophin-Associated Glycoprotein Complex. **2018**, 251, 535-550		13
274	Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression. **2018**, 32, 5090-5103		10
273	Role of ⊞Dystrobrevin in the differentiation process of HL-60 cells. *Experimental Cell Research*, **2018**, 370, 591-600	4.2	1
272	Personalized gene and cell therapy for Duchenne Muscular Dystrophy. *Neuromuscular Disorders*, **2018**, 28, 803-824	2.9	27
271	Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice. *PLoS ONE*, **2018**, 13, e0198408	3.7	1
270	MyD88 is required for satellite cell-mediated myofiber regeneration in dystrophin-deficient mdx mice. **2018**, 27, 3449-3463		7
269	Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations. **2018**, 19, 4		25
268	The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy. **2018**, 6, 179-192		26
267	Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy. **2018**, 183, 54-66		22
266	Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. **2018**, 5, 913-926		18
265	Genome Editing Therapy for Duchenne Muscular Dystrophy. **2018**, 277-285		0
264	Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway. **2018**, 11, 506-512		4
263	Spatial Scale and Structural Heterogeneity in Skeletal Muscle Performance. **2018**, 58, 163-173		3
262	Molecular Therapies for Muscular Dystrophies. **2018**, 20, 27		2

261	Skeletal Muscle Stem Cells. **2019**, 273-293		1
260	Ions concentration in blood samples of SJL/J dystrophic mice strains using X-ray fluorescence spectrometry. **2019**, 1291, 012023		
259	Muscle biopsies in clinical trials for Duchenne muscular dystrophy - PatientsN and caregiversN perspective. *Neuromuscular Disorders*, **2019**, 29, 576-584	2.9	11
258	miR-146a deficiency does not aggravate muscular dystrophy in mdx mice. **2019**, 9, 22		10
257	Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice. **2019**, 127, 1058-1066		4
256	Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas. **2019**, 11,		10
255	A Promising Future for Stem-Cell-Based Therapies in Muscular Dystrophies-In Vitro and In Vivo Treatments to Boost Cellular Engraftment. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	4
254	Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction. **2019**, 34, 1588-1601		15
253	The Added Value of Cardiac Magnetic Resonance in Muscular Dystrophies. **2019**, 6, 389-399		7
252	Development of Novel Micro-dystrophins with Enhanced Functionality. **2019**, 27, 623-635		41
251	sPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19/miR-675/let-7 and miR-21 pathways. **2019**, 10, 82		22
250	Dystrophin Deficiency Leads to Genomic Instability in Human Pluripotent Stem Cells via NO Synthase-Induced Oxidative Stress. **2019**, 8,		19
249	What We Have Learned from 10 Years of DMD Exon-Skipping Trials. **2019**, 745-758		
248	Clinical Perspective of Posttranslational Modifications. **2019**, 37-68		1
247	Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. **2019**, 19, 84		15
246	The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. **2019**, 28, 2189-2200		21
245	Targeted deletion of α1-syntrophin causes a loss of K 4.1 from Müller cell endfeet in mouse retina. **2019**, 67, 1138-1149		5
244	Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy?. **2019**, 52, e12599		5

243	Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study. *Neuromuscular Disorders*, **2019**, 29, 261-268	2.9	19
242	Adiponectin in Myopathies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	7
241	Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. **2019**, 20, 637		16
240	Duchenne muscular dystrophy: Focus on arachidonic acid metabolites. **2019**, 110, 796-802		12
239	Instantaneous frequency as a new approach for evaluating the clinical severity of Duchenne muscular dystrophy through ultrasound imaging. **2019**, 94, 235-241		3
238	PPAR modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy. **2019**, 46, 51-58		9
237	Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2--Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid. **2020**, 63, 2547-2556		8
236	Cultured hippocampal neurons of dystrophic mdx mice respond differently from those of wild type mice to an acute treatment with corticosterone. *Experimental Cell Research*, **2020**, 386, 111715	4.2	3
235	Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy. **2020**, 12, e11019		7
234	Increased Expression of FGF-21 Negatively Affects Bone Homeostasis in Dystrophin/Utrophin Double Knockout Mice. **2020**, 35, 738-752		7
233	Dystroglycan Mediates Clustering of Essential GABAergic Components in Cerebellar Purkinje Cells. **2020**, 13, 164		3
232	Modelling Neuromuscular Diseases in the Age of Precision Medicine. **2020**, 10,		2
231	Reduction of circulating sphingosine-1-phosphate worsens mdx soleus muscle dystrophic phenotype. **2020**, 105, 1895-1906		1
230	Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy. **2021**, 8, 845-863		4
229	Association of genetic variants in migraineurs with and without restless legs syndrome. **2020**, 7, 1942-1950		3
228	Rapid, redox-mediated mechanical susceptibility of the cortical microtubule lattice in skeletal muscle. **2020**, 37, 101730		4
227	Calcium channels linked to altered cellular function and disease. **2020**, 17, 124-137		1
226	Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies. **2020**, 11,		10

225	Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study. *Scientific Reports*, **2020**, 10, 20585	4.9	8
224	Identification of candidate loci for adaptive phenotypic plasticity in natural populations of spadefoot toads. **2020**, 10, 8976-8988		3
223	The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. **2020**, 22, 1332-1345		27
222	16th Meeting of the Interuniversity Institute of Myology (IIM) - Assisi (Italy), October 17-20, 2019: Foreword, Program and Abstracts. **2020**, 30, 9345		
221	Dystrophin Is Required for the Proper Timing in Retinal Histogenesis: A Thorough Investigation on the Mouse Model of Duchenne Muscular Dystrophy. **2020**, 14, 760		2
220	A child with duchenne muscular dystrophy: A case report of a rare diagnosis among Africans. **2020**, 8, 2654-2660		2
219	Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning. **2020**, 25,		
218	Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks. **2020**, 158, 104917		6
217	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. **2020**, 77, 982-991		71
216	DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate Human Cardiac Pathophysiology. **2020**, 8, 535		10
215	Functional specialization of retinal Müller cell endfeet depends on an interplay between two syntrophin isoforms. **2020**, 13, 40		3
214	Wet-Spun Trojan Horse Cell Constructs for Engineering Muscle. **2020**, 8, 18		8
213	Early alterations of the behavioural structure of mice affected by Duchenne muscular dystrophy and tested in open-field. **2020**, 386, 112609		2
212	Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. **2020**, 20, 263-274		24
211	Time-dependent diffusion MRI as a probe of microstructural changes in a mouse model of Duchenne muscular dystrophy. **2020**, 33, e4276		4
210	Pigs with δ-sarcoglycan deficiency exhibit traits of genetic cardiomyopathy. **2020**, 100, 887-899		4
209	AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy. **2020**, 11, 518-533		13
208	Histological features of masticatory muscles after botulinum toxin A injection into the right masseter muscle of dystrophin deficient (mdx-) mice. **2020**, 229, 151464		4

207	Tissue-Specificity of Dystrophin-Actin Interactions: Isoform-Specific Thermodynamic Stability and Actin-Binding Function of Tandem Calponin-Homology Domains. **2020**, 5, 2159-2168		3
206	Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. **2020**, 11, 547-563		37
205	Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills for Everything Together?. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	16
204	Tyrosine phosphorylation as a regulator of dystrophin and beta-dystroglycan interaction: A molecular insight. **2020**, 99, 107623		3
203	Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles. *Nature Communications*, **2020**, 11, 1990	17.4	8
202	TRPCs: Influential Mediators in Skeletal Muscle. **2020**, 9,		9
201	A high-throughput digital script for multiplexed immunofluorescent analysis and quantification of sarcolemmal and sarcomeric proteins in muscular dystrophies. **2020**, 8, 53		5
200	Decreased smooth muscle function, peristaltic activity, and gastrointestinal transit in dystrophic (mdx) mice. **2021**, 33, e13968		7
199	Optical Clearing of Skeletal Muscle Bundles Engineered in 3-D Printed Templates. **2021**, 49, 523-535		5
198	PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy. **2021**, 29, 132-148		5
197	Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice. **2021**, 102, 11-21		2
196	Structural Proteins | Dystrophin: A Multifaceted Protein Critical for Muscle Health. **2021**, 625-638		0
195	Neurological complications of cardiomyopathies. **2021**, 177, 91-109		0
194	Mitochondrial hydrogen sulfide supplementation improves health in the Duchenne muscular dystrophy model. **2021**, 118,		6
193	Impact of estrogen deficiency on diaphragm and leg muscle contractile function in female mdx mice. *PLoS ONE*, **2021**, 16, e0249472	3.7	3
192	RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays. **2021**, 26,		4
191	Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. **2021**, 78, 4867-4891		4
190	Early administration of L-arginine in neonatal mice delays the onset of muscular dystrophy in tibialis anterior (TA) muscle. **2021**, 3, 639-651		1

189	Dystrophie musculaire de Duchenne : Eat actuel et perspectives thEapeutiques. **2021**, 205, 509-518		
188	as a Model System for Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
187	Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways. **2021**, 106, 1597-1611		
186	Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia. **2021**, 14,		1
185	Decreased YAP activity reduces proliferative ability in human induced pluripotent stem cell of duchenne muscular dystrophy derived cardiomyocytes. *Scientific Reports*, **2021**, 11, 10351	4.9	0
184	Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice. **2021**, 30, 1349-1359		2
183	VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy. **2021**, 21, 369-381		1
182	Cellular pathology of the human heart in Duchenne muscular dystrophy (DMD): lessons learned from in vitro modeling. **2021**, 473, 1099-1115		0
181	Efficient precise in vivo base editing in adult dystrophic mice. *Nature Communications*, **2021**, 12, 3719	17.4	8
180	Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. **2021**, 47, 711-723		7
179	Pathological alterations in the gastrointestinal tract of a porcine model of DMD. **2021**, 11, 131		1
178	Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. **2021**, 8, 469-479		8
177	Phospholipids: Identification and Implication in Muscle Pathophysiology. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
176	Electrophysiological analysis of healthy and dystrophic 3-D bioengineered skeletal muscle tissues. **2021**, 321, C749-C759		0
175	Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects. **2021**, 13, 137		0
174	IRE1/XBP1 signaling promotes skeletal muscle regeneration through a cell non-autonomous mechanism.		
173	Investigations on the occurrence of a muscular disorder in Austrian slaughter pigs. **2021**, 7, 51		0
172	Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy. *Nature Communications*, **2021**, 12, 4722	17.4	10

171	New Extensibility and Scripting Tools in the ImageJ Ecosystem. **2021**, 1, e204		0
170	De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle. **2021**, 132, 227-244		6
169	Dystrophin Dp71 Subisoforms Localize to the Mitochondria of Human Cells. **2021**, 11,		
168	Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial. **2021**, 15, 1389-1396		0
167	Quantifying Lower Limb Muscle Stiffness as Ambulation Function Declines in Duchenne Muscular Dystrophy with Acoustic Radiation Force Impulse Shear Wave Elastography. **2021**, 47, 2880-2889		0
166	Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration. *Biomedicines*, **2021**, 9,	4.8	3
165	Shared and distinct mechanisms of skeletal muscle atrophy: A narrative review. **2021**, 71, 101463		1
164	Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. **2021**, 1332, 167-187		20
163	Myotonic Dystrophy and Developmental Regulation of RNA Processing. **2018**, 8, 509-553		20
162	Large Scale Gene Expression Profiles as Tools to Study Skeletal Muscle Adaptation. **2006**, 29-54		1
161	Dysbindin-1 and Its Protein Family. **2009**, 107-241		35
160	The Functional Consequences of Dystrophin Deficiency in Skeletal Muscles. **2007**, 409-433		2
159	MMP-9/TIMP-1 Extracellular Proteolytic System as AP-1 Target in Response to Neuronal Activity. 277-293		1
158	Duchenne Cardiomyopathy Gene Therapy. **2010**, 141-162		6
157	Stretch-induced membrane damage in muscle: comparison of wild-type and mdx mice. **2010**, 682, 297-313		27
156	Redirecting splicing to address dystrophin mutations: molecular by-pass surgery. **2006**, 44, 161-97		5
155	Skeletal Muscle. **2012**, 449-460		2
154	Therapeutic Potential of Skeletal Muscle Plasticity and Slow Muscle Programming for Muscular Dystrophy and Related Muscle Conditions. **2017**, 277-292		4

153	Intracellular Signaling and Regulation of Cardiac Ion Channels. **2004**, 33-41		5
152	Muscle Cell Transplants. **2007**, 289-302		1
151	Dystrophin is required for normal synaptic gain in the Drosophila olfactory circuit. **2019**, 1712, 158-166		1
150	Interleukin-6: A neuro-active cytokine contributing to cognitive impairment in Duchenne muscular dystrophy?. **2020**, 133, 155134		5
149	From diagnosis to therapy in Duchenne muscular dystrophy. **2020**, 48, 813-821		10
148	Role of proteoglycans and glycosaminoglycans in Duchenne muscular dystrophy. **2019**, 29, 110-123		10
147	Therapeutic potential of heat shock protein induction for muscular dystrophy and other muscle wasting conditions. **2018**, 373,		24
146	Smooth muscle cell□extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. **2004**, 113, 668-675		60
145	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. **2004**, 113, 1353-1363		345
144	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. **2004**, 113, 1353-63		154
143	NF-□-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. **2013**, 123, 4821-35		224
142	COUP-TFII regulates satellite cell function and muscular dystrophy. **2016**, 126, 3929-3941		24
141	Immunolocalization of caveolin-1 and caveolin-3 in monkey skeletal, cardiac and uterine smooth muscles. **2002**, 27, 375-82		32
140	Single-transcript multiplex hybridisation reveals unique patterns of dystrophin isoform expression in the developing mammalian embryo. *Wellcome Open Research*, **2020**, 5, 76	4.8	3
139	Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique. **2018**, 9, 4767-4780		4
138	The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophy. **2012**, 4,		4
137	L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. *PLoS ONE*, **2008**, 3, e1762	3.7	32
136	Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotype. *PLoS ONE*, **2008**, 3, e2419	3.7	19

135	Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. *PLoS ONE*, **2012**, 7, e49350	3.7	26
134	Orai1 mediates exacerbated Ca(2+) entry in dystrophic skeletal muscle. *PLoS ONE*, **2012**, 7, e49862	3.7	43
133	Electrical stimuli are anti-apoptotic in skeletal muscle via extracellular ATP. Alteration of this signal in Mdx mice is a likely cause of dystrophy. *PLoS ONE*, **2013**, 8, e75340	3.7	20
132	Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. *PLoS ONE*, **2013**, 8, e81222	3.7	35
131	Low intensity, high frequency vibration training to improve musculoskeletal function in a mouse model of Duchenne muscular dystrophy. *PLoS ONE*, **2014**, 9, e104339	3.7	11
130	Identification of □-Dystrobrevin as a Direct Target of miR-143: Involvement in Early Stages of Neural Differentiation. *PLoS ONE*, **2016**, 11, e0156325	3.7	7
129	Interleukin-1beta (IL-1□)-induced Notch ligand Jagged1 suppresses mitogenic action of IL-1□ on human dystrophic myogenic cells. *PLoS ONE*, **2017**, 12, e0188821	3.7	9
128	Dystrophin-glycoproteins associated in congenital muscular dystrophy: immunohistochemical analysis of 59 Brazilian cases. **2005**, 63, 791-800		7
127	Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations. **2017**, 8, 145-155		20
126	Stem cells: An insight into the therapeutic aspects from medical and dental perspectives. **2015**, 7, S361-71		3
125	Evaluation of multiplex ligation-dependent probe amplification analysis versus multiplex polymerase chain reaction assays in the detection of dystrophin gene rearrangements in an Iranian population subset. **2014**, 3, 72		9
124	A Genome-Wide Association Study Identifies Gene Polymorphism for Restless Legs Syndrome in a Korean Population. **2017**, 14, 830-838		3
123	Cardiac involvement in Duchenne and Becker muscular dystrophy. **2015**, 7, 410-4		41
122	Thrombospondin-4 controls matrix assembly during development and repair of myotendinous junctions. **2014**, 3,		66
121	A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.		
120	SERCA-mediated calcium uptake in the DBA/2J vs C57BL/10 mdx models of Duchenne muscular dystrophy.		
119	Can 1H NMR Derived Metabolic Profiles Contribute to Proteomic Analyses?. **2003**, 39-68		
118	Stem Cells for the Treatment of Muscular Dystrophy: More Than Wishful Thinking?. **2004**, 721-729		

99	Muscular Dystrophy. **2016**, 235-244		
98	Changes in cytosolic Ca2+ dynamics in the sarcoplasmic reticulum associated with the pathology of Duchenne muscular dystrophy. **2016**, 5, 309-312		
97	Dystrophin Degradation in Skeletal Muscles with Lipid Enrichment in Cattle. **2016**, 26, 592-602		
96	Biological Role of TRPC1 in Myogenesis, Regeneration, and Disease. **2017**, 211-230		
95	Duchenne Muscular Dystrophy and Exercise: Structural, Functional, and Biochemical Effects of Exercise Modality in the Skeletal Muscles. **2018**, 57, 321-333		
94	The Heart-Brain Connection in Patients with Duchenne Muscular Dystrophy. **2019**, 1-18		
93	[The pathogenesis of Duchenne muscular dystrophy]. **2019**, 119, 79-81		1
92	Distrofia muscular de Becker con duplicaci□ en el ex□ 5del gen DMD. **2019**, 28,		
91	PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.		
90	The Heart-Brain Connection in Patients with Duchenne Muscular Dystrophy. **2020**, 541-558		
89	Utrophin, MHC and M1/M2 macrophages in GRMD dogs. 21,		
88	Single-transcript multiplex in situ hybridisation reveals unique patterns of dystrophin isoform expression in the developing mammalian embryo. *Wellcome Open Research*, **2020**, 5, 76	4.8	2
87	Muskeldystrophien. **2005**, 282-283		
86	Kontraktionsmechanismen. **2005**, 116-143		
85	The Potential Use of Myogenic Stem Cells in Regenerative Medicine. **2006**, 299-317		
84	Defective Glycosylation and Muscular Dystrophies. 515-526		
83	Molecular Organization of the Postsynaptic Membrane at Inhibitory Synapses. **2008**, 621-660		
82	Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. **2004**, 113, 668-75		26

81	Electrophysiological analysis of healthy and dystrophic 3D bioengineered skeletal muscle tissues.		
80	Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. **2020**, 16, e1009179		2
79	Structure and function of muscle fibers and motor units. 1-19		1
78	Molecular pathogenesis of severe cardiomyopathy in the TO-2 hamster. **2003**, 8, 143-6		9
77	Markers of degeneration and regeneration in Duchenne muscular dystrophy. **2009**, 28, 94-100		35
76	The development of the myotendinous junction. A review. **2012**, 2, 53-63		66
75	Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. **2015**, 34, 9-13		30
74	Gastrocnemius medialis muscle architecture and physiological cross sectional area in adult males with Duchenne muscular dystrophy. **2015**, 15, 154-60		11
73	Evaluation of the Unit Rod surgical instrumentation in Duchenne scoliosis. A retrospective study. **2016**, 9, 437-443		
72	Duchenne Muscular Dystrophy (DMD) Protein-Protein Interaction Mapping. **2017**, 11, 7-14		9
71	Evidence of the involvement of dystrophin Dp71 in corneal angiogenesis. **2019**, 25, 714-721		
70	[A retrospective analysis of 6 children with Duchenne muscular dystrophy]. **2017**, 19, 405-409		
69	Skeletal Ryanodine Receptors Are Involved in Impaired Myogenic Differentiation in Duchenne Muscular Dystrophy Patients. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
68	Dystrophin deficiency affects human astrocyte properties and response to damage. **2021**,		2
67	The IRE1/XBP1 signaling axis promotes skeletal muscle regeneration through a cell non-autonomous mechanism. **2021**, 10,		0
66	Deficiency of Glycosylated Dystroglycan in Ventral Hippocampus Bridges the Destabilization of Gamma-Aminobutyric Acid Type A Receptors With the Depressive-like Behaviors of Male Mice.. *Biological Psychiatry*, **2021**,	7.9	0
65	Implementation of Hospital-Based Supplemental Duchenne Muscular Dystrophy Newborn Screening (sDMDNBS): A Pathway to Broadening Adoption. *International Journal of Neonatal Screening*, **2021**, 7,	2.6	2
64	Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.. *Nucleic Acids Research*, **2022**,	20.1	6

63	Overexpression of the dystrophins Dp40 and Dp40 modifies neurite outgrowth and the protein expression profile of PC12 cells.. *Scientific Reports*, **2022**, 12, 1410	4.9	0
62	Diversity of Dystrophin Gene Mutations and Disease Progression in a Contemporary Cohort of Duchenne Muscular Dystrophy.. *Pediatric Cardiology*, **2022**, 1	2.1	0
61	Two novel RNA-binding proteins identification through computational prediction and experimental validation.. *Genomics*, **2021**, 114, 149-160	4.3	
60	Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via , Satellite, and Immune Cells in Duchenne Muscular Dystrophy.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
59	Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies. *Experimental Cell Research*, **2021**, 410, 112968	4.2	4
58	Growth pattern trajectories in boys with Duchenne muscular dystrophy.. *Orphanet Journal of Rare Diseases*, **2022**, 17, 20	4.2	1
57	Injectable hydrogel microspheres for sustained gene delivery of antisense oligonucleotides to restore the expression of dystrophin protein in duchenne muscular dystrophy. *European Polymer Journal*, **2022**, 166, 111038	5.2	0
56	CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.. *Neurotherapeutics*, **2022**, 1	6.4	5
55	Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.. *Frontiers in Medicine*, **2022**, 9, 859930	4.9	1
54	Dystrophin genetic variants and autism. *Discover Mental Health*, **2022**, 2, 1		
53	Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis.. *PLoS ONE*, **2022**, 17, e0265879	3.7	1
52	Synaptic alterations as a neurodevelopmental trait of Duchenne muscular dystrophy.. *Neurobiology of Disease*, **2022**, 168, 105718	7.5	1
51	Muscular and Tendon Degeneration after Achilles Rupture: New Insights into Future Repair Strategies.. *Biomedicines*, **2021**, 10,	4.8	0
50	Longitudinal assessment of blood-borne musculoskeletal disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy. *Wellcome Open Research*, 6, 354	4.8	0
49	TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD.. *Journal of Translational Medicine*, **2021**, 19, 519	8.5	1
48	Beyond Mendelian Inheritance: Genetic Buffering and Phenotype Variability. *Phenomics*, **2022**, 2, 79-87		0
47	Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis.. *BMC Genomic Data*, **2021**, 22, 57	0	1
46	The Roles of Human Endogenous Retroviruses (HERVs) in Inflammation. *Kosin Medical Journal*, **2021**, 36, 69-78	0.1	0

45	Comparative study of calcium and calcium-related enzymes with differentiation markers in different ages and muscle types in mdx mice. *Histology and Histopathology*, **2020**, 35, 203-216	1.4	3
44	Data_Sheet_1.docx. **2020**,		
43	Video_1.AVI. **2020**,		
42	Image_1.JPEG. **2020**,		
41	Table_1.docx. **2020**,		
40	Pig models for Duchenne muscular dystrophy：from disease mechanisms to validation of new diagnostic and therapeutic concepts. *Neuromuscular Disorders*, **2022**,	2.9	1
39	Physiological Systems in Promoting Frailty.. **2022**, 12, 1-46		2
38	Myxomavirus Serp-1 Protein Ameliorates Inflammation in a Mouse Model of Duchenne Muscular Dystrophy. *Biomedicines*, **2022**, 10, 1154	4.8	
37	Extracellular polysaccharides purified (Polycan) from Aureobasidium pullulans SM-2001 improves pathophysiology of dystrophin-deficient mdx mice. *Molecular and Cellular Toxicology*,	1.6	
36	Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*, **2022**, 23, 6160	6.3	1
35	Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics. *Science Translational Medicine*, **2022**, 14,	17.5	2
34	Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression. *Nature Communications*, **2022**, 13,	17.4	1
33	Temporal regulation of TAK1 to counteract muscular dystrophy.		1
32	Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. *Fundamental Research*, **2022**,		1
31	SERCA function is impaired in skeletal and cardiac muscles from young DBA/2J mdx mice. **2022**, 104972		1
30	Longitudinal assessment of blood-borne musculoskeletal disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy. 6, 354		0
29	A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22. **2022**, 23, 9059		1
28	p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression. **2022**, 933, 175277		0

27	Post-translational Modification in Muscular Dystrophies. **2022**, 71-84	1
26	A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.	0
25	Increased Dp71 in ischemia-reperfusion injured rat heart exerts anti-apoptotic role via enhancing Bcl-2. **2022**, 101951	0
24	Differential venom gland gene expression analysis of juvenile and adult scorpions Androctonus crassicauda. **2022**, 23,	0
23	The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophy. 7, 238	0
22	Proteomic Identification of Markers of Membrane Repair, Regeneration and Fibrosis in the Aged and Dystrophic Diaphragm. **2022**, 12, 1679	1
21	Dp71 Point Mutations Induce Protein Aggregation, Loss of Nuclear Lamina Integrity and Impaired Braf35 and Ibraf Function in Neuronal Cells. **2022**, 23, 11876	0
20	Early Developmental Changes of Muscle Acetylcholine Receptors Are Little Influenced by Dystrophin Absence in mdx Mouse. **2022**, 12, 1861	0
19	Sulfur amino acid supplementation displays therapeutic potential in a C. elegans model of Duchenne muscular dystrophy. **2022**, 5,	1
18	Retinal dystrophins and the retinopathy of Duchenne muscular dystrophy. **2022**, 101137	0
17	Effect of parasitic infection on muscular function of dystrophin gene (Dmd) deficient mouse.	0
16	Dystrophin is a mechanical tension modulator.	0
15	Radiographic, MRI, and CT findings in a young dog with Becker-like muscular dystrophy.	0
14	Is the fundamental pathology in Duchenne muscular dystrophy caused by a failure of glycogenolysis–glycolysis in costameres?. **2023**, 102,	0
13	Spectrum of Genetic Variants in the Dystrophin Gene: A Single Centre Retrospective Analysis of 750 Duchenne and Becker Patients from Southern Italy. **2023**, 14, 214	1
12	Skeletal muscle fat. **2023**, 149-167	0
11	Cell Therapy for Muscular Dystrophy.	0
10	Ion Channels of the Sarcolemma and Intracellular Organelles in Duchenne Muscular Dystrophy: A Role in the Dysregulation of Ion Homeostasis and a Possible Target for Therapy. **2023**, 24, 2229	1

9	The vitamin B3analogue nicotinamide riboside has only very minor effects on reducing muscle damage inmdxmice.	0
8	New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy. **2023**, 867, 147358	0
7	Importance of electromyography in children. **2022**, 4, 8	0
6	Insights into Cell-Specific Functions of Microtubules in Skeletal Muscle Development and Homeostasis. **2023**, 24, 2903	1
5	Modeling Reduced Contractility and Stiffness Using iPSC-Derived Cardiomyocytes Generated From Female Becker Muscular Dystrophy Carrier. **2023**,	0
4	Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. **2023**, 15, 778	0
3	Assessment of Extracellular Volume Fraction in Becker Muscular Dystrophy by Using MR Fingerprinting.	0
2	Trichinella spiralis (Owen, 1835) Induces Increased Dystrophin Expression in Invaded Cross-striated Muscle.	0
1	Change in the spectrum of detected mutations in the <I>DMD</I> gene depending on the methodological capabilities of the laboratory. **2023**, 13, 33-43	0